Background

• The standard of care for non-small cell lung cancer (NSCLC) patients is immune checkpoint inhibitors (ICI) alone or with chemotherapy, though most patients fail to achieve a durable response
• In the KEYNOTE-189 trial, treatment-naïve NSCLC patients who received pembrolizumab (anti-PD-1) in addition to standard chemotherapy achieved a 48% objective response, compared to 19% in patients receiving chemotherapy alone
• However, only 0.5% of patients in the KEYNOTE-189 trial achieved a complete response, with only 34% of pembrolizumab-treated patients alive and progression-free at 12 months
• Unmet Need: While ICIs have improved outcomes for NSCLC, there remains a persistent unmet need for additional therapies that prolong survival and deliver a durable response